Photon no-clean homocysteine kit and preparation method thereof

Through the connection of seven reagents of the photon-free cleaning homocysteine ​​kit, the problems of insufficient detection sensitivity and cumbersome process are solved, and high sensitivity, wide linear range and efficient detection are achieved, which is suitable for applications in small and medium-sized medical institutions.

CN118937687APending Publication Date: 2024-11-12BEIJING DAWEITIAN TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411097501.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing homocysteine ​​detection methods have insufficient sensitivity, poor repetition, narrow linear range and cumbersome and time-consuming detection processes, making them difficult to popularize in small and medium-sized medical institutions.

Method used

Provide a photon-free cleaning homocysteine ​​kit, including reducing protection reagents, hydrolyzing separators, luminescent antibody reagents, detection antibody reagents, bead-coated reagents and enzymatic luminescent reagents. Through the subtle connection of seven reagents, Form a spatial series effect to improve detection sensitivity and efficiency.

Benefits of technology

Significantly improve the sensitivity of homocysteine ​​assay, broaden the linear range, and achieve efficient cleaning-free detection, suitable for clinical laboratory applications, with a sensitivity increase of nearly 350 times, and the linear range extends from 0-50μmol/L to 0-5000μmol/L , the detection efficiency is greatly improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937687A_ABST
    Figure CN118937687A_ABST
Patent Text Reader

Abstract

The invention discloses a photon no-clean homocysteine kit and a preparation method thereof, and belongs to the technical field of immunodetection, the photon no-clean homocysteine kit comprises a reduction protection reagent R1, a hydrolysis separation agent R2, a luminescent antibody reagent R3, a detection antibody reagent R4, a magnetic bead coating reagent R5, a denaturation reagent R6 and an enzymatic luminescent reagent R7 according to a volume ratio of (0.01-13): (0.05-15): (0.03-15): (0.11-12): (0.06-10): (0.08-16): (0.03-14). According to the kit provided by the invention, the background effect is greatly reduced, the sensitivity of the kit is improved by about 350 times compared with that of a traditional homocysteine (HCY) determination kit (an enzyme circulation method), and the lowest detection limit of the kit can reach 0.034 mu mol / L; the linear width is increased to 0-5000 [mu] mol / L from 0-50 [mu] mol / L of a traditional homocysteine (HCY) determination kit (enzyme cycling method), and the problems that in the prior art, a homocysteine detection method is insufficient in sensitivity, poor in repeatability, narrow in linear range and tedious and time-consuming in detection process are solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of immunoassay technology, specifically to a photon-based, wash-free, luminescent, wash-free homocysteine ​​reagent kit and its preparation method. Background Technology

[0002] Homocysteine ​​(HCY) is a sulfhydryl-containing amino acid, mainly derived from dietary methionine. It is an important intermediate product in the metabolism of methionine and cysteine, and does not participate in protein synthesis itself.

[0003] The metabolic pathway of homocysteine ​​(HCY) mainly involves two aspects: Firstly, under the action of methionine synthase reductase (MS), approximately half of HCY reacts with methyltetrahydrofolate to produce methionine and tetrahydrofolate; secondly, approximately half of HCY, through the transsulfurization pathway, forms cystathionine under the action of cystathionine β-synthase (CBS), which is further metabolized into cysteine. In addition, HCY can also be converted into homocysteine ​​thiolactone (HTL) under the action of aminoacyl-tRNA synthetase. Clinically, HCY levels are closely related to various diseases. High levels of HCY are considered an important risk factor for cardiovascular disease. It can cause arterial damage by stimulating the blood vessel wall, leading to inflammation and plaque formation, ultimately resulting in obstruction of blood flow to the heart. Furthermore, hyperhcyemia is also associated with birth defects such as neural tube defects. Therefore, accurate measurement of blood HCY concentration is crucial for clinical diagnosis and treatment.

[0004] Currently, the main methods used for HCY detection on the market are enzymatic cycling and magnetic microparticle immunochemiluminescence. While enzymatic cycling is simple to operate, its low sensitivity, especially in the clinically significant low concentration range (e.g., ≤12 μmol / L), results in significant repeatability deviations and a narrow linear range, typically only detecting samples up to 50 μmol / L, thus limiting its application. Magnetic microparticle immunochemiluminescence, while improving sensitivity, has a more complex testing procedure, usually requiring multiple cleaning cycles, taking a long time (at least one hour), and demanding high-performance equipment, making it difficult to widely adopt in small and medium-sized medical institutions.

[0005] Therefore, there is an urgent need for a photon-based, wash-free, luminescent, wash-free homocysteine ​​reagent kit and its preparation method, which has high sensitivity, good repeatability, wide linear range, and simple and rapid operation for HCY detection, in order to solve the problems existing in the current technology. Summary of the Invention

[0006] To address these issues, this invention provides a photon-based, wash-free, luminescent, wash-free homocysteine ​​reagent kit and its preparation method, thereby solving the problems of insufficient sensitivity, poor repeatability, narrow linear range, and cumbersome and time-consuming detection procedures in existing homocysteine ​​detection methods.

[0007] To achieve the above objectives, the present invention provides the following technical solution:

[0008] According to a first aspect of the present invention, a photon-based, wash-free homocysteine ​​reagent kit is provided, comprising a reducing and protecting reagent R1, a hydrolytic separation agent R2, a luminescent antibody reagent R3, a detection antibody reagent R4, a magnetic bead coating reagent R5, a denaturing reagent R6, and an enzyme-catalyzed luminescent reagent R7, wherein the volume ratio is (0.01-13):(0.05-15):(0.03-15):(0.11-12):(0.06-10):(0.08-16):(0.03-14);

[0009] The reducing protective reagent R1 includes: 0.05-1 wt% tris(2-carboxyethyl)phosphine, 0.01-1 wt% dithiothreitol, 0.01-1.8 wt% protective agent, and 0.01-1.2 mol / L Tris buffer;

[0010] The hydrolysis separation agent R2 comprises: 0.001-1 wt% S-adenosyl-homocysteine ​​hydrolase, 0.01-2 wt% enzyme separation agent, and 0.01-1.2 mol / L Tris buffer;

[0011] The luminescent antibody reagent R3 comprises: 0.01-10 wt% S-adenosine-homocysteine ​​monoclonal antibody-peroxidase complex, 0.02-13 wt% enhancer, and 0.01-8 mol / L Tris buffer;

[0012] The detection antibody reagent R4 comprises: 0.05-5 wt% of avidinized S-adenosine-homocysteine ​​monoclonal antibody-hydrophilic acridine ester complex, 0.01-12 wt% of enhancer, and 0.01-5 mol / L of Tris buffer;

[0013] The magnetic bead coating reagent R5 comprises: 0.05-5 wt% streptavidin-coated magnetic bead solution and 0.05-5 mol / L Tris buffer;

[0014] The denaturing reagent R6 comprises: 0.01-6.5 wt% denaturing reagent, 0.03-8.7 mol / L ammonia solution, and 0.06-1 mol / L Tris buffer;

[0015] The enzyme-catalyzed luminescence reagent R7 comprises: 0.5-15 wt% catalyst, 0.8-12 wt% enhancer, 0.05-1 mol / L Tris buffer, and 0.07-7.5 mol / L acetic acid solution.

[0016] Furthermore, the volume ratio of the reducing protective reagent R1 to the sample is (0.05-1.5):(0.01-2);

[0017] The volume ratio of hydrolysis separating agent R2 to the sample is (0.03-1.8):(0.01-3);

[0018] The volume ratio of luminescent antibody reagent R3 to the sample is (0.06-2.4):(0.02-5);

[0019] The volume ratio of the detection antibody reagent R4 to the sample is (0.05-1.5):(0.45-6).

[0020] Furthermore, the magnetic beads are 1-5 μm tosylate magnetic beads, and the volume ratio of the magnetic bead coating reagent R5 to the detection antibody R4 is (0.06-12):(0.04-8).

[0021] Furthermore, the volume ratio of the denaturing reagent R6 to the magnetic bead coating reagent R5 is (0.06-12):(0.08-16).

[0022] Furthermore, the volume ratio of the enzyme-catalyzed luminescence reagent R7 to the denaturing reagent R6 is (0.04-10):(0.06-12).

[0023] Furthermore, the luminescent, wash-free homocysteine ​​reagent kit also includes calibrators, quality control samples, and instrument needle cleaning solution.

[0024] According to a second aspect of the present invention, a method for preparing the above-described photon-based wash-free homocysteine ​​reagent kit is provided, comprising the following steps:

[0025] S1. Preparation of reducing protective reagent R1: Prepare a solution containing 0.05-1 wt% tris(2-carboxyethyl)phosphine, 0.01-1 wt% dithiothreitol, 0.01-1.8 wt% protective agent, and 0.01-1.2 mol / L Tris buffer.

[0026] S2. Preparation of hydrolysis separating agent R2: Prepare a solution of 0.001-1 wt% S-adenosine-homocysteine ​​hydrolase, 0.01-2 wt% enzyme separating agent, and 0.01-1.2 mol / L Tris buffer.

[0027] S3. Preparation of luminescent antibody reagent R3: Prepare a solution of 0.01-10 wt% S-adenosine-homocysteine ​​monoclonal antibody-peroxidase complex, 0.02-13 wt% enhancer, and 0.01-8 mol / L Tris buffer.

[0028] S4. Preparation of antibody R4: Prepare a solution of 0.05-5 wt% avidinized S-adenosine-homocysteine ​​monoclonal antibody-hydrophilic acridine ester complex, 0.01-12 wt% enhancer, and 0.01-5 mol / L Tris buffer.

[0029] S5. Preparation of magnetic bead coating reagent R5: Prepare a streptavidin-coated magnetic bead solution: 0.05-5 wt% Tris buffer 0.05-5 mol / L solution;

[0030] S6. Preparation of denaturing reagent R6: a solution of denaturing reagent 0.01-6.5 wt%, ammonia solution 0.03-8.7 mol / L, and Tris buffer 0.06-1 mol / L;

[0031] S7. Preparation of enzyme-catalyzed luminescence reagent R7: a solution of 0.5-15 wt% catalyst, 0.8-12 wt% enhancer, 0.05-1 mol / L Tris buffer, and 0.07-7.5 mol / L acetic acid solution.

[0032] Furthermore, the preparation of the luminescent antibody reagent R3 specifically includes:

[0033] ①Activate peroxidase, centrifuge and discard the supernatant, then wash repeatedly with buffer;

[0034] ② After adding the coupling agent and incubating, centrifuge and discard the supernatant;

[0035] ③ S-adenosine-homocysteine ​​monoclonal antibody was added to buffer and purified through a column;

[0036] ⑤ S-adenosine-homocysteine ​​monoclonal antibody is passed through a dialysis membrane and concentrated;

[0037] ⑥ Add the S-adenosine-homocysteine ​​monoclonal antibody from step ⑤ to step ②, mix well, incubate, centrifuge, discard the supernatant and add diluent;

[0038] ⑦ Add the blocking solution, mix well, wash and centrifuge;

[0039] ⑧ Discard the supernatant and add preservation solution for preservation.

[0040] Furthermore, the preparation of the detection antibody reagent R4 specifically includes:

[0041] ① Activate the hydrophilic acridine ester, centrifuge and discard the supernatant, then wash repeatedly with buffer;

[0042] ② After adding the coupling agent and incubating, centrifuge and discard the supernatant;

[0043] ③ Avidinization treatment with S-adenosine-homocysteine ​​monoclonal antibody;

[0044] ④ S-adenosine-homocysteine ​​monoclonal antibody is passed through a dialysis membrane and concentrated;

[0045] ⑤ Add the S-adenosine-homocysteine ​​monoclonal antibody from step ④ to step ②, mix well, incubate, centrifuge, discard the supernatant and add diluent;

[0046] ⑥ Add the blocking solution, mix well, wash and centrifuge;

[0047] ⑦ Discard the supernatant and add preservation solution for preservation.

[0048] Furthermore, the preparation of the magnetic bead coating reagent R5 specifically includes the following steps:

[0049] ① Activation of magnetic beads;

[0050] ② Add coupling agent, mix well, incubate, and then centrifuge;

[0051] ③Streptavidin is added to buffer solution and purified through a column;

[0052] ④Streptavidin is concentrated via dialysis membrane;

[0053] ⑤ Add the concentrated streptavidin from step ④ to step ②, incubate, mix well, centrifuge, discard the supernatant and add buffer.

[0054] ⑥ Add blocking solution, mix well and couple, centrifuge after 4 hours, discard supernatant and add preservation solution to suspend;

[0055] ⑦ Discard the supernatant and add preservation solution for resuspension and storage.

[0056] The present invention has the following advantages:

[0057] 1. This invention achieves a spatial cascade effect through the subtle connection of seven reagents. The sensitivity of the kit prepared by this invention is nearly 350 times higher than that of the traditional homocysteine ​​(HCY) assay kit (enzyme cycling method), with a detection limit as low as 0.034 μmol / L. Furthermore, the linear range is significantly broadened from 0-50 μmol / L to 0-5000 μmol / L, and no hook effect is observed even at test concentrations as high as 10000 μmol / L, ensuring the accuracy of detection results over a wide concentration range.

[0058] 2. The photon-based wash-free homocysteine ​​(HCY) assay kit provided by this invention breaks the historical limitation of testing homocysteine ​​solely on biochemical platforms. Although homocysteine ​​detection has been available on magnetic microparticle immunochemiluminescence platforms in recent years, with improved sensitivity compared to the HCY assay kit (enzyme cycling method), the testing process is cumbersome, requiring one to multiple washes, and is time-consuming, taking at least one hour per sample. Furthermore, it places stringent requirements on instrument performance, making it difficult for small and medium-sized hospitals to widely adopt. The emergence of the photon-based wash-free homocysteine ​​assay provides hospital laboratories with another detection platform, achieving high sensitivity, wide linear range, and efficient wash-free detection, greatly improving detection efficiency and convenience, making it highly suitable for clinical laboratory applications. Attached Figure Description

[0059] To more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are merely exemplary, and those skilled in the art can derive other embodiments based on the provided drawings without creative effort.

[0060] The structures, proportions, sizes, etc. illustrated in this specification are only for the purpose of assisting those skilled in the art in understanding and reading the content disclosed herein, and are not intended to limit the conditions under which the present invention can be implemented. Therefore, they have no substantial technical significance. Any modifications to the structure, changes in the proportions, or adjustments to the size, without affecting the effects and objectives that the present invention can produce, should still fall within the scope of the technical content disclosed in the present invention.

[0061] Figure 1 The standard curve of photon-based wash-free homocysteine ​​provided by this invention;

[0062] Figure 2 The linear range of the photon-based wash-free homocysteine ​​reagent kit provided in Example 1 of this invention;

[0063] Figure 3 Correlation analysis of the photon-based wash-free homocysteine ​​kit provided in Example 1 of this invention. Detailed Implementation

[0064] The following specific embodiments illustrate the implementation of the present invention. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. Obviously, the described embodiments are only some, not all, of the embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0065] This invention provides a photon-based, wash-free homocysteine ​​kit, comprising: a reducing and protecting reagent R1, a hydrolytic separation agent R2, a luminescent antibody reagent R3, a detection antibody reagent R4, a magnetic bead coating reagent R5, a denaturing reagent R6, and an enzyme-catalyzed luminescent reagent R7, wherein the volume ratio of the seven components is (0.01-13):(0.05-15):(0.03-15):(0.11-12):(0.06-10):(0.08-16):(0.03-14), preferably 1:2:2:2:3:3:3, thereby enabling the kit to achieve a detection limit of 0.001 μmol / L.

[0066] The reducing protective reagent R1 includes: tris(2-carboxyethyl)phosphine 0.05-1 wt%, dithiothreitol 0.01-1 wt%, protective agent 0.01-1.8 wt%, and Tris buffer 0.01-1.2 mol / L;

[0067] Preferably, the reducing protective reagent R1 comprises a solution of 0.25 wt% tris(2-carboxyethyl)phosphine, 0.05 wt% dithiothreitol, 0.04 wt% protective agent, and 0.5 mol / L Tris buffer.

[0068] The volume ratio of the reducing protective reagent R1 to the sample is (0.05-1.5):(0.01-2). Optimization can improve the linear correlation coefficient r of the kit. To improve the correlation of the test samples, the volume ratio of the reducing protective reagent R1 to the sample can preferably be 1:1. If it is less than the lower limit or greater than the upper limit, the measured values ​​of high-value and low-value samples will deviate significantly from the target concentration values, resulting in a poor fitting correlation coefficient r between the measured values ​​and the target concentration values.

[0069] Specifically, the hydrolysis separation agent R2 comprises: 0.001-1 wt% S-adenosyl-homocysteine ​​hydrolase, 0.01-2 wt% enzyme separation agent, and 0.01-1.2 mol / L Tris buffer; preferably, the hydrolysis separation agent R2 comprises a solution of 0.25% S-adenosyl-homocysteine ​​hydrolase, 0.04 wt% enzyme separation agent, and 0.5 mol / L Tris buffer, with the volume ratio of hydrolysis separation agent R2 to the sample being (0.03-1.8):(0.01-3), which can convert free homocysteine ​​into S-adenosyl-homocysteine ​​(SAH); to improve the repeatability of the test samples and reduce the coefficient of variation (CV), the volume ratio of hydrolysis separation agent R2 to the sample is preferably 1:2; if it is less than the lower limit or greater than the upper limit, it will affect the stability of the hydrolysis separation agent R2, resulting in a poor coefficient of variation (CV) during repeatability testing.

[0070] The luminescent antibody reagent R3 comprises: 0.01-10 wt% of S-adenosine-homocysteine ​​monoclonal antibody-peroxidase complex, 0.02-13 wt% of enhancer, and 0.01-8 mol / L of Tris buffer; preferably, the luminescent antibody reagent R3 comprises a solution of 0.5% S-adenosine-homocysteine ​​monoclonal antibody-peroxidase complex, 0.03 wt% of enhancer, and 0.5 mol / L of Tris buffer. The volume ratio of the luminescent antibody reagent R3 to the sample is (0.06-2.4):(0.02-5), preferably 1:2. After optimization, no hook effect will occur, and the concentration can be extended to 5000 μmol / L. Even if the test concentration of the calibrator is as high as 10000 μmol / L, no hook effect will occur. If the concentration is less than the lower limit or greater than the upper limit, a hook effect will occur. This is because the homocysteine ​​monoclonal antibody content is too low, and homocysteine ​​is relatively excessive, resulting in a post-band effect. If the homocysteine ​​monoclonal antibody content is too high, and homocysteine ​​is relatively low, an early-band effect will occur.

[0071] The detection antibody R4 comprises: 0.05-5 wt% of avidinized S-adenosine-homocysteine ​​monoclonal antibody-hydrophilic acridine ester complex, 0.01-12 wt% of enhancer, and 0.01-5 mol / L Tris buffer; preferably, the detection antibody R4 comprises a solution of 2.5 wt% of avidinized S-adenosine-homocysteine ​​monoclonal antibody-hydrophilic acridine ester complex, 0.05 wt% of enhancer, and 0.5 mol / L Tris buffer. The volume ratio of antibody reagent R4 to sample is (0.05-1.5):(0.45-6), preferably 1:2. After optimization, no hook effect will occur, and this ratio can be extended to 5000 μmol / L. Even if the test concentration of the calibrator is as high as 10000 μmol / L, no hook effect will occur. If the value is less than the lower limit or greater than the upper limit, a hook effect will occur. This is because the homocysteine ​​monoclonal antibody content is too low, and homocysteine ​​is relatively excessive, resulting in a post-band effect. If the homocysteine ​​monoclonal antibody content is too high, and homocysteine ​​is relatively low, an early-band effect will occur.

[0072] The magnetic bead coating reagent R5 comprises: 0.05-5 wt% streptavidin-coated magnetic bead solution and 0.05-5 mol / L Tris buffer; preferably, the magnetic bead coating reagent R5 comprises a solution of 0.5 wt% streptavidin-coated magnetic bead solution and 0.5 mol / L Tris buffer. The volume ratio of the magnetic bead coating reagent R5 to the detection antibody R4 is (0.06-12):(0.04-8), preferably 3:2. After this ratio, the magnetic bead coating reagent R5 and the detection antibody R4 bind sufficiently, resulting in a high luminescence value; if the value is below the lower limit, the luminescence value will be very low; if the value is above the upper limit, it will result in waste of the magnetic bead reagent.

[0073] Denaturing reagent R6 comprises: 0.01-6.5 wt% denaturing reagent, 0.03-8.7 mol / L ammonia solution, and 0.06-1 mol / L Tris buffer; preferably, denaturing reagent R6 comprises a solution of 2.5% denaturing reagent, 0.25 wt% ammonia solution, and 0.5 mol / L Tris buffer. The volume ratio of denaturing reagent R6 to magnetic bead coating reagent R5 is (0.06-12):(0.08-16), preferably 3:3; preferably, denaturing reagent R6 will not cause aggregation reaction of magnetic bead coating reagent R5. If the value is less than the lower limit or greater than the upper limit, aggregation reaction of magnetic bead coating reagent R5 will occur, because excessive denaturing reagent R6 will destroy magnetic bead coating reagent R5, while insufficient denaturing reagent R6 will result in less obvious aggregation of magnetic bead coating reagent R5 and reagents R1-R4.

[0074] The enzyme-catalyzed luminescent reagent R7 comprises: 0.5-15 wt% catalytic agent, 0.8-12 wt% enhancer, 0.05-1 mol / L Tris buffer, and 0.07-7.5 mol / L acetic acid solution; preferably, the enzyme-catalyzed luminescent reagent R7 comprises a solution of 10.5 wt% catalytic agent, 5 wt% enhancer, 0.5 mol / L Tris buffer, and 0.5 mol / L acetic acid solution. The volume ratio of enzyme-catalyzed luminescent reagent R7 to denaturing reagent R6 is (0.04-10):(0.06-12), preferably 3:3. Preferably, the enzyme-catalyzed luminescent reagent R7 exhibits a rapid decomposition effect on the aggregation products formed by denaturing reagent R6, magnetic bead coating reagent R5, detection antibody R4, and luminescent antibody reagent R3. During this decomposition effect, a large number of short photons are generated and amplified step-by-step by the enhancer. The enhanced short photons are received by the receiver, and the photon value is emitted. At the same time, the concentration value corresponding to the photon value can be derived from the calibrator, thereby indirectly obtaining the concentration value in the serum. If the value is less than the lower limit or greater than the upper limit, there will be insufficient photon quantity, which will affect the reagent sensitivity. On the other hand, an excessive amount of enzyme-catalyzed luminescent reagent R7 will cause the short photons to be released rapidly, making it difficult for the instrument to capture them.

[0075] In practice, a 100-test kit of the luminescent, wash-free homocysteine ​​reagent kit may include: 3 mL of reduction protection reagent R1, 6 mL of hydrolysis separation agent R2, 6 mL of luminescent antibody reagent R3, 6 mL of detection antibody reagent R4, 9 mL of magnetic bead coating reagent R5, 9 mL of denaturation reagent R6, and 9 mL of enzyme-catalyzed luminescent reagent R7. Each human test may include: 30 μL of reduction protection reagent R1, 60 μL of hydrolysis separation agent R2, 60 μL of luminescent antibody reagent R3, 60 μL of detection antibody reagent R4, 90 μL of magnetic bead coating reagent R5, 90 μL of denaturation reagent R6, and 90 μL of enzyme-catalyzed luminescent reagent R7.

[0076] The photon-based, wash-free homocysteine ​​kit also includes calibrators and quality control samples. The calibrators consist of six different concentrations of homocysteine ​​(0 μmol / L, 10 μmol / L, 50 μmol / L, 500 μmol / L, 2500 μmol / L, and 5000 μmol / L), primarily for calibrating the kit. The quality control samples are homocysteine ​​at specified concentrations (10 μmol / L and 500 μmol / L), primarily for quality control purposes, used to assess whether the system's test values ​​are within acceptable limits on the day of testing.

[0077] Considering levitation performance, the magnetic beads can be 1-5 μm toluenesulfonyl magnetic beads; for better levitation, the particle size of the toluenesulfonyl magnetic beads is preferably 3 μm. If the particle size is greater than the upper limit, it will affect the levitation performance of the magnetic beads; if the particle size is less than the lower limit, it will affect the magnetism of the magnetic beads.

[0078] The following description, in conjunction with specific embodiments, provides further details.

[0079] Example 1: Preparation of a luminescent, wash-free homocysteine ​​reagent kit

[0080] 1.1 Preparation of reducing and protecting reagent R1

[0081] Take a 1L container and add approximately 800g of hot purified water (50-60℃); prepare a 0.5mol / L Tris buffer solution, then add 0.25g of tris(2-carboxyethyl)phosphine (TCEP) and stir until completely dissolved; add 0.5g of dithiothreitol (DTT) and stir until completely dissolved; add 0.4g of the protective agent and stir until completely dissolved; bring the volume to 1000g with purified water to obtain a solution containing 0.25wt% tris(2-carboxyethyl)phosphine, 0.05wt% dithiothreitol, and 0.04wt% protective agent; then filter it through a 0.22μm filter to remove impurities and bacteria; store at 4℃.

[0082] 1.2 Preparation of hydrolysis separating agent R2

[0083] Take a 1L container and add about 800g of hot purified water (50-60℃); prepare a 0.5mol / L Tris buffer solution, then add 0.25g of S-adenosine homocysteine ​​hydrolase and stir until completely dissolved; add 0.4g of enzyme separator and stir until completely dissolved; bring the volume up to 1000g with purified water to obtain a solution containing 0.25wt% S-adenosine homocysteine ​​hydrolase and 0.04wt% enzyme separator.

[0084] 1.3 Preparation of luminescent antibody reagent R3

[0085] ① Take 1g of peroxidase, add it to 10mL of propanol solution, centrifuge at 12000g and discard the supernatant, add propanol solution again, and repeat centrifugation 2-3 times; add dimethylformamide and mix to dissolve the precipitate, add 1g of sodium periodate and mix for 30min; centrifuge at 12000g and discard the supernatant.

[0086] ② Take 1 mg of S-adenosine-homocysteine ​​monoclonal antibody, add 100 mM MES buffer, add 100 mM MES buffer to the purification column and pass it through the purification column. Then, pass the S-adenosine-homocysteine ​​monoclonal antibody through a dialysis membrane and load it into the dialysis membrane (pore size cutoff is 30 kDa). Add 5 g of PEG20000 powder outside the dialysis membrane. The PEG20000 powder will precipitate water from the dialysis membrane. Concentrate to 10 mg / mL.

[0087] ③ Mix step ② with step ①, vortex for 4 hours, then add 100mM MES buffer to wash, centrifuge at 12000g for 5 minutes, and discard the supernatant.

[0088] ④ Add 100mM MES blocking solution containing 1% BSA, mix well, vortex for 4 hours, wash and centrifuge, centrifuge at 12000g for 5 minutes, and discard the supernatant.

[0089] ⑤ Preparation of preservation solution: Prepare 1000 mL of 0.5 mol / L Tris buffer, take 800 mL and add it to a beaker, add 0.3 g of enhancer and mix for 2 h. Balance to 1 L with 0.5 mol / L Tris buffer and filter through a 0.22 μm filter to remove impurities and bacteria; store at 4℃.

[0090] ⑥ Add the S-adenosine-homocysteine ​​monoclonal antibody-peroxidase complex to the preservation solution to prepare a solution containing 0.5 wt% S-adenosine-homocysteine ​​monoclonal antibody-peroxidase complex and 0.03 wt% enhancer, and store at 4℃.

[0091] 1.4 Preparation of antibody detection reagent R4

[0092] ① The preparation involves taking 1g of hydrophilic acridine ester, adding 10mL of dimethylformamide, and stirring to dissolve the precipitate for 15min;

[0093] ② Add ammonium sulfate until it is saturated, then centrifuge at 12000g for 5 minutes and discard the supernatant;

[0094] ③ Take 1 mg of S-adenosine-homocysteine ​​monoclonal antibody, add 1 g of avidin and mix well for 5 min;

[0095] ④ S-adenosine-homocysteine ​​monoclonal antibody was passed through a dialysis membrane and loaded into the dialysis membrane (with a pore size of 30kd). 5g of PEG20000 powder was added outside the dialysis membrane. The PEG20000 powder would precipitate water from the dialysis membrane. The solution was concentrated to 10mg / mL.

[0096] Add 100mM MES blocking solution containing 1% BSA, mix well, vortex for 4 hours, wash and centrifuge, centrifuge at 12000g for 5 minutes, and discard the supernatant.

[0097] ⑤ Preparation of preservation solution: Prepare 1000mL of 0.5mol / L Tris buffer, take 800mL and add it to a beaker, add 0.3g of enhancer and mix for 2h. Balance to 1L with 0.5mol / L Tris buffer and filter it through a 0.22μm filter to remove impurities and bacteria. The storage temperature is 4℃.

[0098] ⑥ Add the avidinized S-adenosine-homocysteine ​​monoclonal antibody-hydrophilic acridine ester complex to the preservation solution to prepare a solution containing 2.5 wt% avidinized S-adenosine-homocysteine ​​monoclonal antibody-hydrophilic acridine ester complex and 0.05 wt% enhancer. Store at 4°C.

[0099] 1.5 Preparation of magnetic bead coating reagent R5

[0100] ① Take 10 mL of 100 mg / mL toluenesulfonyl magnetic beads (containing 100 mg of magnetic beads with a particle size of 1.5 μm), centrifuge at 5000 g for 5 min, remove the original supernatant, add 10 mL of 100 mM MES buffer with a pH of 6.5, and mix on a blood mixer for 5 min.

[0101] ② Add coupling agent to the solution obtained in ①, mix well, incubate at 37℃, and centrifuge at 5000g for 5min; the coupling agent is ammonium sulfate and boric acid in a weight ratio of 1:2; the weight ratio of boric acid to magnetic microspheres is 1:1.

[0102] ③ Reconstitute streptavidin with 50mM potassium carbonate buffer at pH 8.0 to a concentration of 1mg / mL, and then pass it through a purification column.

[0103] ④ The streptavidin purified in step ③ is loaded into a dialysis membrane (with a pore size of 30kd). 5g of PEG20000 powder is added outside the dialysis membrane. The PEG20000 powder will precipitate the water inside the dialysis membrane. The concentration is then reduced to 10mg / mL.

[0104] ⑤ Add the concentrated streptavidin solution from step ④ to step ②, keep the temperature at 37℃ for 12 hours, centrifuge at 5000g for 5 minutes, discard the supernatant, and add 2.5 mL of 100Mm MES buffer with a pH of 6.5.

[0105] ⑥ Add 1.5 wt% bovine serum albumin solution to the solution obtained in step ⑤, and centrifuge at 5000g for 5 min after 12 h;

[0106] ⑦ Remove the supernatant from the solution obtained in step ⑥ using a pipette and add the preservation solution, which consists of 0.5M Trisl solution, and store at 4℃.

[0107] 1.6 Preparation of denaturing reagent R6

[0108] Take a 1L container and add about 800g of hot purified water (50-60℃); prepare a 0.5mol / L Tris buffer solution, add 2.5mL of ammonia solution, and stir until completely dissolved; add 2.5g of denaturing reagent and stir until completely dissolved; then filter it through a 0.22μm filter to remove impurities and bacteria, and store it at 4℃.

[0109] 1.7 Preparation of enzyme-catalyzed luminescent reagent R7

[0110] Take a 1L container and add about 800g of hot purified water (50-60℃); prepare a 0.5mol / L Tris buffer solution and a 0.5mol / L acetic acid solution, then add 105g of the activator reagent; stir until completely dissolved; add 50g of the enhancer reagent and stir until completely dissolved; then filter it through a 0.22μm filter to remove impurities and bacteria, and store at 4℃.

[0111] 1.8 Assemble the above reagents into a reagent boat.

[0112] 1.9 Preparation of calibrators and quality control samples:

[0113] Preparation of calibrators: 500 mL of the preservation solution (20 mM Tris-HCl, 0.12 wt% BSA, 0.15 wt% PC300, 0.025 wt% Tween 20, 0.12 wt% NaCl solution, pH 8.0) was measured using a 1000 mL graduated cylinder and added to a glass vial. Then, 75 μmol of homocysteine ​​was pipetted into the vial. The vial was then placed on a blood homogenizer and mixed at room temperature for 30 min to obtain 150 μmol of calibrator. Homocysteine ​​at a concentration of mol / L was prepared into five other homocysteine ​​concentrations (0 μmol / L, 10 μmol / L, 50 μmol / L, 500 μmol / L, 2500 μmol / L, and 5000 μmol / L) using diluents (20 mM Tris-HCl, 0.12 wt% BSA, 0.15 wt% PC300, 0.025 wt% Tween 20, and 0.12 wt% NaCl solution) and dispensed.

[0114] Preparation of quality control sample: Using a 100mL graduated cylinder, measure 100mL of preservation solution (20mM Tris-HCl, 0.12wt% BSA, 0.15wt% PC300, 0.025wt% Tween 20, and 0.12wt% NaCl solution) and add it to a glass bottle. Use a pipette to add 1μmol of homocysteine ​​to the glass bottle. Then place the glass bottle on a blood homogenizer and mix at room temperature for 30min to obtain 10μmol / L homocysteine. Dilute it with diluent (20mM Tris-HCl, 0.12wt% BSA, 0.15wt% PC300, 0.025wt% Tween 20, and 0.12wt% NaCl solution) to prepare 10μmol / L homocysteine ​​solution for dispensing.

[0115] Example 2: Establishment of the HCY Standard Curve

[0116] 60 μL of calibrator was mixed with 30 μL of reducing protection reagent R1, 60 μL of hydrolysis separation agent R2, 60 μL of luminescent antibody reagent R3, 60 μL of detection antibody reagent R4, and 90 μL of magnetic bead coating reagent R5. The mixture was incubated at 37°C for 8 min. Then, 90 μL of denaturing reagent R6 was added, and the mixture was incubated at 37°C for 1 min. Finally, 90 μL of enzyme-catalyzed luminescent reagent R7 was added, and the mixture was mixed for 4 seconds. The photon signal values ​​were then measured using a fully automated immunoassay analyzer, and the average values ​​were recorded. The mean photon signal was obtained, and the specific data are shown in Table 1. A standard curve can be established based on the theoretical concentration and the mean photon signal. Figure 1 It is a standard curve established based on the data in Example 1.

[0117] Table 1. Results of HCY standard curve test luminescence values ​​in Example 1

[0118] Theoretical concentration Test 1 Test 2 Photon mean Fitted concentration deviation 0 514.74 503.16 509 0.00 0.00 10 3476.63 3449.56 3463 9.97 -0.31 50 16269.44 15599.96 15935 49.91 -0.18 500 164361.76 157326.86 160844 497.01 -0.60 2500 791614.94 760764.57 776190 2508.50 0.34 5000 1417711.79 1439863.15 1428788 5011.22 0.22

[0119] Example 3: Detection of homocysteine ​​using a photon-based, wash-free reagent kit.

[0120] 3.1 Minimum detection limit

[0121] The sample was tested using a diluent (20 mM Tris-HCl, 0.12 wt% BSA, 0.15 wt% PC300, 0.025 wt% Tween 20, and 0.12 wt% NaCl solution). The measurements were repeated 20 times, and the photon values ​​(relative luminescence values) of the 20 measurements were obtained. The mean (Ave) and standard deviation (SD) were calculated, yielding Ave + 2 × SD. A two-point regression was performed based on the concentration-RLU between the zero-concentration calibrator and adjacent calibrators to derive a linear equation. The RLU value of M + 2 SD was substituted into the equation to calculate the corresponding concentration value, which is the limit of detection. The results are shown in Table 2 below. As shown in Table 2, the photon-based wash-free homocysteine ​​kit of the present invention can detect samples as low as 0.034 μmol / L, which is nearly 350 times more sensitive than the homocysteine ​​(HCY) assay kit (enzyme cycling method) which can only detect up to 12 μmol / L. This demonstrates that the photon-based wash-free homocysteine ​​kit of the present invention is highly sensitive.

[0122] Table 2 Photon values ​​of calibrator diluents

[0123]

[0124]

[0125] 3.2 Repeatability Analysis

[0126] Using low-value samples (homocysteine ​​concentration of 10 μmol / L) and medium-to-high-value samples (homocysteine ​​concentration of 500 μmol / L), repeat the test 10 times, calculate the mean (M) and standard deviation (SD) of the 10 detected concentrations, and calculate the coefficient of variation (CV) according to formula (2). The coefficient of variation (CV) should not be greater than 10.0%.

[0127] CV=SD / M×100%……………………(2)

[0128] In the formula:

[0129] CV – Coefficient of Variation;

[0130] SD – Standard deviation of the test results;

[0131] M – The average value of the test results.

[0132] Table 3 Low Value Test Repeatability Test

[0133]

[0134]

[0135] Table 4 shows the repeatability of high-value tests.

[0136] Number of tests Photon value Concentration value 1 160016 494.46 2 162277 501.43 3 160542 496.08 4 157994 488.22 5 155770 481.37 6 156515 483.67 7 159689 493.45 8 155201 479.62 9 157889 487.90 10 159653 493.34 Ave 158555 489.95 SD 2153 6.64 CV 1.36% 1.35%

[0137] As can be seen from the data in Tables 3 and 4, the low-value sample (10 μmol / L) and the medium-to-high-value sample (500 μmol / L) were tested 10 times. The average value (M) and standard deviation (SD) of the 10 detected concentrations were calculated. The coefficient of variation (CV) was calculated according to formula (2). The coefficients of variation (CV) were 1.72% and 1.35%, respectively, both less than 10.0%. This shows that the kit of Example 1 of the present invention conforms to the kit standard YY / T1258-2015.

[0138] 3.3 Linear Analysis

[0139] High-value samples approaching the upper limit of the linear range were diluted to at least five concentrations: 5000 μmol / L, 2500 μmol / L, 500 μmol / L, 50 μmol / L, 10 μmol / L, and 0.5 μmol / L. Each concentration was tested three times, and the average value was calculated. The deviation (CV) was then determined, and the results are shown in Table 5. The logarithm of the three test values ​​and the target concentration (the diluted sample concentration) was used for linear fitting using the least squares method, and the linear correlation coefficient (R) was calculated. Table 5 shows that the repeatability of each gradient is less than 10%, and the deviation between the average of the three test values ​​and the target concentration is less than 10%. The correlation coefficient (R) is also relatively high. 2 ≥0.9900 (see) Figure 2 This demonstrates that the linear range of the HCY kit of the present invention is sufficiently wide to fully meet clinical requirements.

[0140] Table 5. Detection results of homocysteine ​​(HCY) at different concentrations, and related statistical indicators.

[0141]

[0142] 3.4 Specificity Analysis

[0143] L-cysteine ​​at a concentration of not less than 100 mmol / L and L-glutathione at a concentration of 100 mmol / L were directly tested using the HCY kit of Example 1 of this invention. The results are shown in Table 6. As can be seen from Table 6, the test results of tests 1-5 are lower than the limit of detection of the HCY kit. This indicates that the HCY kit of Example 1 of this invention has specificity.

[0144] Table 6. Results of different interfering substances detected using the homocysteine ​​(HCY) kit.

[0145]

[0146] 3.5 Correlation Analysis

[0147] This embodiment collected 50 clinical serum samples and tested them using the kit from Embodiment 1 of this invention. The test results (i.e., the test values ​​in the table) were compared with the test results (i.e., the hospital values ​​in the table) of a traditional homocysteine ​​(HCY) assay kit (enzyme cycling method, using a Roche biochemical analyzer) using statistical analysis such as correlation regression. The results are shown in Table 7 below. Figure 3 As shown. From Figure 3 As can be seen from the results, the fitted equation for the correlation line is y = 0.9939x + 0.2432, and the correlation coefficient is R. 2 =0.9944, which indicates that the HCY kit of Example 1 of the present invention has a high correlation with the traditional homocysteine ​​(HCY) assay kit (enzyme cycling method) and the accuracy is very consistent, which meets the kit standard YY / T1258—2015.

[0148] Table 7 shows the results of testing 50 clinical serum samples using the kit from Example 1 and a conventional homocysteine ​​(HCY) assay kit.

[0149] Test serial number Hospital Value Test value Test serial number Hospital Value Test value μmol / L μmol / L μmol / L μmol / L μmol / L 1 16.43 16.93 26 9.29 9.49 2 15.23 16.22 27 13.43 14.74 3 8.22 7.91 28 8.33 8.85 4 9.98 9.51 29 5.87 6.21 5 9.45 9.11 30 44.99 44.56 6 9.51 10.01 31 6.28 6.07 7 16.43 16.09 32 9.09 10.27 8 17.99 18.06 33 69.94 66.83 9 16.77 17.11 34 8.82 9.57 10 19.98 19.32 35 23.43 22.77 11 16.42 15.34 36 6.38 6.77 12 17.74 19.01 37 9.86 8.13 13 6.04 5.06 38 9.23 10.23 14 35.37 35.61 39 50.34 50.45 15 8.92 9.21 40 9.78 8.24 16 10.12 10.87 41 5.23 6.14 17 25.45 26.65 42 8.75 8.34 18 42.56 43.21 43 20.23 21.55 19 10.32 10.17 44 13.23 12.14 20 40.91 44.61 45 12.39 12.28 21 42.9 43.22 46 6.85 6.87 22 31.8 32.05 47 33.62 32.45 23 26.06 27.04 48 6.39 6.29 24 22.28 23.61 49 19.69 18.66 25 24.06 25.17 50 4.16 4.08

[0150] Conclusion: The HCY kit of Example 1 of this invention shows high correlation and consistency with the traditional homocysteine ​​(HCY) assay kit (enzyme cycling method), providing accurate and reliable detection results. For most samples, the deviation between the test values ​​and hospital values ​​is within an acceptable range, indicating that the kit has good accuracy. While some samples showed certain differences between the test values ​​and hospital values, these differences were minor overall and did not affect the overall performance of the kit. These conclusions support the effectiveness and reliability of the HCY kit of Example 1 of this invention and comply with the relevant standard YY / T1258-2015.

[0151] Although the present invention has been described in detail above with general descriptions and specific embodiments, modifications or improvements can be made to it, which will be obvious to those skilled in the art. Therefore, all such modifications or improvements made without departing from the spirit of the present invention fall within the scope of protection claimed by the present invention.

Claims

1. A photon-free cleaning homocysteine ​​kit, characterized in that: It includes a reduction protection reagent R1, a hydrolysis separation agent R2, a luminescent antibody reagent R3, a detection antibody reagent R4, a magnetic bead coating reagent R5, a denaturation reagent R6 and an enzyme luminescent reagent R7, and the volume ratio thereof is (0.01-13): (0.05-15): (0.03-15): (0.11-12): (0.06-10): (0.08-16): (0.03-14); The reducing protection reagent R1 comprises: 0.05-1 wt% of tris(2-carboxyethyl)phosphine, 0.01-1 wt% of dithiothreitol, 0.01-1.8 wt% of a protective agent and 0.01-1.2 mol / L of a Tris buffer; The hydrolysis separation agent R2 comprises: 0.001-1wt% of S-adenosine-homocysteine ​​hydrolase, 0.01-2wt% of enzyme separation agent and 0.01-1.2mol / L of Tris buffer; The luminescent antibody reagent R3 comprises: 0.01-10wt% of S-adenosine-homocysteine ​​monoclonal antibody-peroxidase complex, 0.02-13wt% of enhancer and 0.01-8mol / L of Tris buffer; The detection antibody reagent R4 comprises: 0.05-5wt% of avidinized S-adenosine-homocysteine ​​monoclonal antibody-hydrophilic acridinium ester complex, 0.01-12wt% of enhancer and 0.01-5mol / L of Tris buffer; The magnetic bead coating reagent R5 comprises: 0.05-5wt% of a magnetic bead liquid reagent coated with streptavidin and 0.05-5mol / L of a Tris buffer; The denaturing agent R6 comprises: 0.01-6.5wt% of denaturing agent, 0.03-8.7mol / L of ammonia solution and 0.06-1mol / L of Tris buffer; The enzyme-promoted luminescent reagent R7 comprises: 0.5-15wt% of a promoter, 0.8-12wt% of an enhancer, 0.05-1mol / L of a Tris buffer solution and 0.07-7.5mol / L of an acetic acid solution.

2. The photon-free cleaning homocysteine ​​kit according to claim 1, characterized in that: The volume ratio of the reduction protection reagent R1 to the sample is (0.05-1.5): (0.01-2); The volume ratio of hydrolysis separation agent R2 to sample is (0.03-1.8): (0.01-3); The volume ratio of the luminescent antibody reagent R3 to the sample is (0.06-2.4): (0.02-5); The volume ratio of the detection antibody reagent R4 to the sample is (0.05-1.5):(0.45-6).

3. The photon-free cleaning homocysteine ​​kit according to claim 1, characterized in that: The magnetic beads are tosyl magnetic beads of 1-5 μm, and the volume ratio of the magnetic bead coating reagent R5 to the detection antibody R4 is (0.06-12): (0.04-8).

4. The photon-free cleaning homocysteine ​​kit according to claim 1, characterized in that: The volume ratio of the denaturing reagent R6 to the magnetic bead coating reagent R5 is (0.06-12): (0.08-16).

5. The photon-free cleaning homocysteine ​​kit according to claim 1, characterized in that: The volume ratio of the enzymatic luminescent reagent R7 to the denaturing reagent R6 is (0.04-10): (0.06-12).

6. The photon-free cleaning homocysteine ​​kit according to claim 1, characterized in that: The luminescent cleaning-free homocysteine ​​test kit also includes a calibrator, a quality control product and an instrument needle cleaning solution.

7. The method for preparing the photon-free cleaning homocysteine ​​kit according to any one of claims 1 to 6, characterized in that: The following steps are involved: S1. Preparation of reducing protection reagent R1: prepare a solution of 0.05-1wt% tris(2-carboxyethyl)phosphine, 0.01-1wt% dithiothreitol, 0.01-1.8wt% protective agent, and 0.01-1.2mol / L Tris buffer; S2. Preparation of hydrolysis separation agent R2: Prepare S-adenosine - homocysteine ​​hydrolase 0.001-1wt%, enzyme separation agent 0.01-2wt%, Tris buffer 0.01-1.2mol / L solution; S3. Preparation of luminescent antibody reagent R3: prepare a solution of 0.01-10wt% S-adenosine-homocysteine ​​monoclonal antibody-peroxidase complex, 0.02-13wt% enhancer, and 0.01-8mol / L Tris buffer; S4. Preparation of detection antibody R4: prepare a solution of avidinized S-adenosine-homocysteine ​​monoclonal antibody-hydrophilic acridinium ester complex 0.05-5wt%, enhancer 0.01-12wt%, Tris buffer 0.01-5mol / L; S5. Preparation of magnetic bead coating reagent R5: Prepare streptavidin-coated magnetic bead liquid reagent: 0.05-5wt%, Tris buffer 0.05-5mol / L solution; S6. Preparation of denaturing reagent R6: a solution of 0.01-6.5wt% denaturing reagent, 0.03-8.7mol / L ammonia solution, and 0.06-1mol / L Tris buffer; S7. Preparation of enzymatic luminescent reagent R7: a solution of 0.5-15wt% accelerator, 0.8-12wt% enhancer, 0.05-1mol / L Tris buffer, and 0.07-7.5mol / L acetic acid solution.

8. The method for preparing the photon-free cleaning homocysteine ​​kit according to claim 7, characterized in that: The preparation of the luminescent antibody reagent R3 specifically includes: ① Activate peroxidase, centrifuge and discard the supernatant, and wash repeatedly with buffer; ② After adding the coupling agent and incubating, centrifuge and discard the supernatant; ③S-adenosine-homocysteine ​​monoclonal antibody was added to the buffer solution and passed through the purification column; ⑤S-adenosine-homocysteine ​​monoclonal antibody is passed through a dialysis membrane and concentrated; ⑥ Add the S-adenosine-homocysteine ​​monoclonal antibody prepared in step ⑤ to step ②, mix well, incubate, centrifuge, discard the supernatant and add diluent; ⑦ Add blocking solution, mix well, wash and centrifuge; ⑧Discard the supernatant and add preservation solution for storage.

9. The method for preparing the photon-free cleaning homocysteine ​​kit according to claim 7, characterized in that: The preparation of the detection antibody reagent R4 specifically includes: ① Activate the hydrophilic acridinium ester, centrifuge and discard the supernatant, and wash repeatedly with buffer; ② After adding the coupling agent and incubating, centrifuge and discard the supernatant; ③ Avidinization of S-adenosine-homocysteine ​​monoclonal antibody; ④S-adenosine-homocysteine ​​monoclonal antibody is passed through a dialysis membrane and concentrated; ⑤ Add the S-adenosine-homocysteine ​​monoclonal antibody prepared in step ④ to step ②, mix well, incubate, centrifuge, discard the supernatant and add diluent; ⑥Add blocking solution, mix well, wash and centrifuge; ⑦Discard the supernatant and add preservation solution for storage.

10. The method for preparing the photon-free cleaning homocysteine ​​kit according to claim 7, characterized in that: The preparation of the magnetic bead coating reagent R5 specifically includes the following steps: ① Activation of magnetic beads; ② Add coupling agent, mix well, incubate and centrifuge; ③ Add streptavidin to the buffer solution and pass through the purification column; ④ Streptavidin is concentrated through a dialysis membrane; ⑤ Add the concentrated streptavidin in step ④ to step ②, incubate, mix and centrifuge, discard the supernatant and add buffer; ⑥ Add blocking solution and mix well for coupling. Centrifuge after 4 hours, discard the supernatant and resuspend in preservation solution; ⑦Discard the supernatant and add preservation solution to suspend and store.